Mangoceuticals Reports 336% Sales Growth for $99 Monthly Testosterone Replacement Therapy Program

Mangoceuticals, operating under the MangoRx and PeachesRx brands, announced significant initial success for its recently launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month. The program includes doctor visits, consultations, lab work and prescribed medication, providing a comprehensive solution for men's hormone health needs. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%, indicating both strong market demand and efficient marketing strategies.

The company described this growth as reflecting increasing demand for convenient hormone health solutions delivered through its telehealth platform. MangoRx expects TRT to serve as a primary growth driver alongside oral formulations including PRIME by MangoRx powered by Kyzatrex. This strategic focus comes as the company seeks to expand its presence in the global TRT market, which is estimated to reach approximately $2.1 billion to $2.2 billion in 2025 according to industry projections. The company's approach combines pharmaceutical-based products with telemedicine services, creating an integrated healthcare delivery model.

MangoRx's current offerings include treatments for erectile dysfunction, hair growth, hormone replacement therapies, and weight management, all accessible through their secure telemedicine platform. The company's prescription process involves review by licensed medical providers, with approved medications fulfilled and discreetly shipped through MangoRx's partner compounding pharmacy directly to patients' doorsteps. This model addresses privacy concerns while providing convenient access to men's health treatments. The company's mission and additional product information can be found at https://www.MangoRx.com.

The announcement was made through BioMedWire, a specialized communications platform focusing on developments in biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that provides various communication services including wire distribution, article syndication, press release enhancement, and social media distribution. The platform aims to help companies reach investors, influencers, consumers, journalists and the general public through targeted communication strategies. Additional information about BioMedWire's services is available at https://www.BioMedWire.com.